• Most Popular
  • Most Shared

India Ranbaxy launches its first authorised generic

Mon Jul 30, 2007 7:10am EDT

Stocks

   

MUMBAI, July 30 (Reuters) - India's Ranbaxy Laboratories Ltd. (RANB.BO) said on Monday it had launched its first authorised generic drug, Isoptin SR, in the U.S. market, after an agreement with FSC Laboratories.

Isoptin SR is a branded drug used to treat hypertension and the market for its generic form was worth $122.2 million, Ranbaxy, India's largest drug maker by sales, said in a statement.

It said the drug faced limited competition, mainly from two firms. Ranbaxy's shares closed 0.5 percent higher at 376.70 rupees in a flat Mumbai market.

((Reporting by Himangshu Watts, editing by Mark Williams; Reuters Messaging: himangshu.watts.reuters.com@reuters.net +91 22 663 9030)) Keywords: RANBAXY GENERIC/

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nBOM287948



More from Reuters

Photo

Honda expands airbag recall as more Toyotas probed

TOKYO/DETROIT (Reuters) - Honda Motor Co said it would recall another 440,000 cars around the world for faulty airbags as rival Toyota Motor Corp faced further probes over its largest-ever safety crisis. | Video

» More Top News
Chairman of the Federal Reserve Ben Bernanke testifies before the Senate Banking, Housing and Urban Affairs Committee on Capitol Hill in Washington July 22, 2009. REUTERS/Kevin Lamarque
John Kemp:

The Fed needs a new storyline

It's irrelevant whether the Fed sells its assets back to the market. What matters is whether and when it's prepared to raise rates.  Commentary 

Economy
A worker drives a Toyota Motor Corp's newly assembled Prius hybrid vehicle onto a trailer near the company's plant in Toyota, central Japan February 9, 2010.REUTERS/Yuriko Nakao
Reuters Breakingviews:

Toyota's troubles in overdrive

The cost of Toyota's recall nightmare is nothing compared to the price of fixing its battered reputation.  Commentary 

Autos